Posted by Michael Wonder on 04 Jan 2022
Genprex receives U.S. FDA fast track designation for Reqorsa immunogene therapy in combination with Keytruda for the treatment of non-small-cell lung cancer
3 January 2022 - Second FDA fast track designation further validates the potential of Reqorsa.
Genprex today announced that the U.S. FDA has granted fast track designation for the Company’s lead drug candidate, Reqorsa immunogene therapy, in combination with Merck's Keytruda in patients with histologically-confirmed unresectable stage III or IV non-small-cell lung cancer whose disease progressed after treatment with Keytruda.
